| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Fibroblast growth factor (FGF) 19/21/23 is an endocrine FGF. FGF23 regulates mineral metabolism and FGF21 is a metabolic hormone that is crucial in glucose and lipid homeostasis. We assessed the relationships between the serum FGF21/23 levels measured by ELISA and vascular parameters, renal outcomes and cardiac function in CKD patients.
We showed that the serum FGF21 level is significantly associated with vascular disorders, including endothelial dysfunction and vascular calcification, independent of the glucose and lipid profiles. We demonstrated that the serum FGF21 level is significantly associated with the renal outcomes. In addition, the serum FGF21 and FGF23 concentrations were independently associated with the diastolic and systolic functions, respectively.
|
